AbbVie in Charts:Skyrizi and Rinvoq continue double-digitY/Y expansion

AbbVie reported Q3 earnings with revenue of $17.4B, beating estimates by $50M. Non-GAAP EPS was $3.82, exceeding expectations by $0.05. The company raised its full-year guidance, driven by strong sales of Skyrizi and Rinvoq, which offset declines in Humira sales.

Original reporting
Published Oct 30, 2026, 12:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

Earnings beat and guidance raise could drive ABBV stock higher

02

Market read

AbbVie's earnings beat is a key driver for healthcare sector performance

03

What to watch

Humira decline may accelerate if biosimilar competition intensifies

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

Article aggregates AbbVie's Q3 earnings highlights and chart data

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

Q3 earnings beat with EPS $3.82 (+$0.05) and revenue $17.4B (+$50M), FY guidance raised

Expected impact

likely upside as market prices in beat and raised guidance

Evidence & confidence

Strong growth in Skyrizi and Rinvoq offsets Humira decline, indicating continued revenue momentum

Market effects

Boosts biotech and pharma sector sentiment

Supports US healthcare stocks

May lift global pharma ETFs

Counterpoint

Patent cliff risk could pressure future sales

Key entities

  • AbbVie

    US pharma company

Related articles

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.

$ABBVHighAI 9/10

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

AbbVie will pay up to $2.54 billion to develop cancer treatments with private German biotech Disco Pharmaceuticals, including a $40 million upfront fee and milestone payments. Disco will handle research, with AbbVie having exclusive licensing rights. The deal focuses on AND-gated bispecific therapeutics for solid tumors, with Disco aiming to select a candidate in late 2024.